ER+/HER2- BREAST CANCER
Clinical trials for ER+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for ER+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Matched conditions: ER+/HER2- BREAST CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill combo aims to fight advanced cancers that stopped responding to prior therapies
Disease control Recruiting nowThis study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…
Matched conditions: ER+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Aminex Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy aims to boost immune response in hard-to-treat breast cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…
Matched conditions: ER+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for advanced breast cancer: experimental drug FWD1802 enters human trials
Disease control Recruiting nowThis study tests a new drug called FWD1802 in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part. The study has…
Matched conditions: ER+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Forward Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy aims to control advanced breast cancer
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, olaparib and estradiol, in post-menopausal women with advanced ER+/HER2- breast cancer that has spread or returned. The goal is to find the best dose for future studies. About 6 participants will be enrolled.
Matched conditions: ER+/HER2- BREAST CANCER
Phase: PHASE1 • Sponsor: Mary D Chamberlin • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gene mutation may alter how breast cancer responds to hormone therapy
Knowledge-focused Recruiting nowThis study looks at how breast cancer cells change after a short course of hormone therapy in women with and without a BRCA2 gene mutation. Researchers will measure a protein called Ki67, which indicates how fast cancer cells are growing. The goal is to see if BRCA2 carriers have…
Matched conditions: ER+/HER2- BREAST CANCER
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC